Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00038519 · ClinicalTrials.gov registry record · Phase 2
Amprenavir/Ritonavir or Saquinavir/Ritonavir in HIV-Infected Subjects Following Failure With Kaletra as Their Second Protease Inhibitor
A Phase 2 study, sponsored by Abbott.
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT00038519 is a Phase 2 study that has completed, run by Abbott. The registered enrollment target is 16 participants.
The verdict
NCT00038519, a Phase 2 study, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of this study is to study the safety and efficacy of Amprenavir/ritonavir or saquinavir/ritonavir in HIV infected patients that have failed Kaletra as their second protease inhibitor based HAART.
Interventions
- DRUG Amprenavir/ritonavir
- DRUG Saquinavir/ritonavir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2001-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00038519
The ClinicalTrials.gov registry entry for NCT00038519 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Amprenavir/ritonavir is the first listed.
NCT00038519 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00038519 about?
NCT00038519 is a clinical study titled "Amprenavir/Ritonavir or Saquinavir/Ritonavir in HIV-Infected Subjects Following Failure With Kaletra as Their Second Protease Inhibitor". The purpose of this study is to study the safety and efficacy of Amprenavir/ritonavir or saquinavir/ritonavir in HIV infected patients that have failed Kaletra as their second protease inhibitor based HAART.
What is the current status of trial NCT00038519?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2001-04.
What interventions are being tested in trial NCT00038519?
The interventions under investigation include: Amprenavir/ritonavir (DRUG), Saquinavir/ritonavir (DRUG).
Who is sponsoring clinical trial NCT00038519?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.